Breaking News Instant updates and real-time market news.

CPIX

Cumberland

$5.29

-0.13 (-2.40%)

, TBPH

Theravance Biopharma

$24.00

-1.21 (-4.80%)

08:34
11/06/18
11/06
08:34
11/06/18
08:34

Cumberland to acquire Vibativ from Theravance Biopharma

Cumberland Pharmaceuticals (CPIX) announced that it has entered into a definitive agreement to acquire Vibativ from Theravance Biopharma (TBPH). Under the terms of the agreement, Cumberland will assume full responsibility for the product including its marketing, distribution, manufacturing and regulatory activities. Cumberland will support Vibativ in the United States through its established hospital sales organization. The company expects to selectively expand its sales force, medical science liaison and corporate teams to ensure the needed support of Vibativ as well as its oncology and acute care brands. The financial terms include a $20M payment to Theravance Biopharma upon closing, a $5M additional payment in early 2019, and tiered royalties of up to 20% on future U.S. net product sales. Cumberland expects that the addition of Vibativ will be accretive to the company's earnings. The transaction is expected to close in mid-November, pending satisfaction of customary closing conditions. Cumberland will provide additional remarks on its upcoming third quarter 2018 earnings call.

CPIX

Cumberland

$5.29

-0.13 (-2.40%)

TBPH

Theravance Biopharma

$24.00

-1.21 (-4.80%)

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

  • 27

    Nov

  • 12

    Dec

CPIX Cumberland
$5.29

-0.13 (-2.40%)

04/17/18
RILY
04/17/18
INITIATION
Target $9.25
RILY
Buy
Cumberland initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Andrew D'Silva started Cumberland Pharmaceuticals with a Buy rating and $9.25 price target. The company's base business "more than justifies" the current valuation while its pipeline offers "game-changing" potential, D'Silva tells investors in a research note.
TBPH Theravance Biopharma
$24.00

-1.21 (-4.80%)

05/09/18
LEER
05/09/18
NO CHANGE
Target $31
LEER
Outperform
Theravance Biopharma price target lowered to $31 from $41 at Leerink
Leerink analyst Geoffrey Porges lowered his price target for Theravance Biopharma to $31 from $41 after the company reported Q1 operational results and announced the discontinuation of its independent development of velusetrag in gastroparesis based on feedback from the FDA about the requirement for large phase III safety and efficacy study as a requirement for approval. The analyst reiterates an Outperform rating on the shares.
08/01/18
PIPR
08/01/18
NO CHANGE
Target $55
PIPR
Overweight
Theravance Biopharma price target raised to $55 from $45 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren raised his price target for Theravance Biopharma (TBPH) to $55 saying the proof of concept demonstrated for TD-9855 in neurogenic orthostatic hypotension compare favorably to Lundbeck's Northera. Considering Northera is run-rating at $250M-$300M about four years post launch with minimal patient penetration of the target population, a differentiated TD-9855 could ultimately achieve $500M-plus in peak sales, Van Buren tells investors in a research note. Further, the analyst believes an accelerated approval could be possible. He reiterates an Overweight rating on Theravance Biopharma.
09/27/18
PIPR
09/27/18
NO CHANGE
Target $55
PIPR
Overweight
Theravance financial flexibility, assets underappreciated, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren says recent meetings with Theravance Biopharma management support his Overweight rating on the shares. The Trelegy royalty stream could potentially be monetized in the near-term as a source of non-dilutive financing, which would alleviate concerns regarding the need for cash, a significant portion of the current bear thesis, Van Buren tells investors in a research note. Further, he notes that management remains confident in a Yupelri approval on November 13. The analyst continues to recommend that investors own Theravance shares as he believes both its financial flexibility and current assets are underappreciated.
10/23/18
PIPR
10/23/18
NO CHANGE
PIPR
Overweight
Piper says Theravance data shows 'disruptive potential' of oral JAK inhibitor
After Theravance Biopharma (TBPH) presented four-week data from the Phase Ib ulcerative colitis study of TD-1473, a gut-selective pan-JAK inhibitor for the treatment of inflammatory bowel disease, at the United European Gastroenterology Week, Piper Jaffray analyst Tyler Van Buren said the data provides substantial proof of concept and shows the "disruptive potential" that could lead to "multi-billion" global sales for Theravance and partner Janssen (JNJ). He maintains an Overweight rating on Theravance shares.

TODAY'S FREE FLY STORIES

AIMT

Aimmune

$23.70

0.73 (3.18%)

, AZN

AstraZeneca

$40.95

0.515 (1.27%)

04:55
02/23/19
02/23
04:55
02/23/19
04:55
Conference/Events
The American Academy of Asthma, Allergy & Immunology to hold annual meeting »

AAAAI Annual Meeting 2019…

AIMT

Aimmune

$23.70

0.73 (3.18%)

AZN

AstraZeneca

$40.95

0.515 (1.27%)

TEVA

Teva

$17.28

0.03 (0.17%)

NVS

Novartis

$90.77

0.26 (0.29%)

DNA

Bought by RHHBY

$0.00

(0.00%)

SHPG

Shire

$0.00

(0.00%)

REGN

Regeneron

$422.43

3.77 (0.90%)

SNY

Sanofi

$41.20

-0.13 (-0.31%)

ALK

Alaska Air

$62.35

-0.48 (-0.76%)

ABT

Abbott

$76.40

1.26 (1.68%)

CVS

CVS Health

$62.00

-0.33 (-0.53%)

KALV

KalVista

$20.74

-0.04 (-0.19%)

BCRX

BioCryst

$8.99

0.32 (3.69%)

OPTN

Optinose

$7.31

0.02 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 04

    Mar

  • 04

    Mar

  • 04

    Mar

  • 07

    Mar

  • 11

    Mar

  • 11

    Mar

  • 12

    Mar

  • 18

    Mar

  • 19

    Mar

  • 22

    Mar

  • 28

    Apr

  • 13

    May

  • 18

    May

ETFC

E-Trade

$48.89

0.65 (1.35%)

04:55
02/23/19
02/23
04:55
02/23/19
04:55
Conference/Events
E-Trade to hold Education Day »

Education Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

TEX

Terex

$35.29

-0.3 (-0.84%)

19:01
02/22/19
02/22
19:01
02/22/19
19:01
Hot Stocks
Terex to sell Demag Mobile Cranes business to Tadano for $215M enterprise value »

Terex announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

CZR

Caesars

$9.05

-0.37 (-3.93%)

18:34
02/22/19
02/22
18:34
02/22/19
18:34
Hot Stocks
Canyon Partners: Caesars shareholders' value best served by open sale process »

Canyon Partners issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$20.85

0.17 (0.82%)

, BA

Boeing

$424.05

6.57 (1.57%)

18:11
02/22/19
02/22
18:11
02/22/19
18:11
Periodicals
Brazilian judge suspends Embraer-Boeing deal talks, Reuters reports »

A Brazilian judge…

ERJ

Embraer

$20.85

0.17 (0.82%)

BA

Boeing

$424.05

6.57 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 11

    Mar

  • 14

    Mar

  • 28

    May

BXG

Bluegreen Vacations

$14.47

0.55 (3.95%)

18:02
02/22/19
02/22
18:02
02/22/19
18:02
Earnings
Bluegreen Vacations reports Q4 EPS 27c, consensus 24c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

SM

SM Energy

$16.88

-0.13 (-0.76%)

17:57
02/22/19
02/22
17:57
02/22/19
17:57
Recommendations
SM Energy analyst commentary at MUFG »

SM Energy's higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AN

AutoNation

$37.22

-1.15 (-3.00%)

17:47
02/22/19
02/22
17:47
02/22/19
17:47
Syndicate
Breaking Syndicate news story on AutoNation »

AutoNation files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

TSLA

Tesla

$294.60

3.42 (1.17%)

, NSANY

Nissan

$0.00

(0.00%)

17:42
02/22/19
02/22
17:42
02/22/19
17:42
Periodicals
Tesla's Model 3 was the highest-selling EV globally in 2018, Verge reports »

Tesla's (TSLA) Model…

TSLA

Tesla

$294.60

3.42 (1.17%)

NSANY

Nissan

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 18

    Mar

  • 19

    Mar

FSFG

First Savings Financial Group

$51.33

0.22 (0.43%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Hot Stocks
First Savings Financial raises quarterly dividend to 16c per share from 15c »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$110.97

1.5 (1.37%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Periodicals
Employees demand Microsoft cancel $480M U.S. Army contract, Reuters says »

Several Microsoft workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 01

    Mar

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 07

    Mar

  • 18

    Mar

ENT

Global Eagle

$2.66

(0.00%)

17:23
02/22/19
02/22
17:23
02/22/19
17:23
Hot Stocks
Global Eagle to cut workforce by roughly 15% »

As previously disclosed,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:15
02/22/19
02/22
17:15
02/22/19
17:15
General news
Breaking General news story  »

New York Federal Reserve…

NOC

Northrop Grumman

$288.84

2.54 (0.89%)

17:13
02/22/19
02/22
17:13
02/22/19
17:13
Hot Stocks
Northrop Grumman exec Kalan sells 4,312 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYB

LyondellBasell

$89.14

0.63 (0.71%)

17:07
02/22/19
02/22
17:07
02/22/19
17:07
Syndicate
Breaking Syndicate news story on LyondellBasell »

LyondellBasell files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCCO

Technical Comm Corp

$2.76

0.17 (6.56%)

17:06
02/22/19
02/22
17:06
02/22/19
17:06
Hot Stocks
Technical Comm Corp to submit plan to regain compliance with Nasdaq by March 4 »

Technical Comm Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFU

InfuSystem

$4.15

0.04 (0.97%)

17:01
02/22/19
02/22
17:01
02/22/19
17:01
Hot Stocks
InfuSystem announces settlement of derivative lawsuit »

InfuSystem Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALU

Kaiser Aluminum

$108.22

-1.9 (-1.73%)

17:01
02/22/19
02/22
17:01
02/22/19
17:01
Hot Stocks
Kaiser Aluminum names Neal West as new CFO »

Kaiser Aluminum announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDR

Alder Biopharmaceuticals

$14.35

0.19 (1.34%)

17:00
02/22/19
02/22
17:00
02/22/19
17:00
Hot Stocks
Alder Biopharmaceuticals submits eptinezumab BLA to FDA »

Alder BioPharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

RF

Regions Financial

$16.24

-0.01 (-0.06%)

16:59
02/22/19
02/22
16:59
02/22/19
16:59
Syndicate
Breaking Syndicate news story on Regions Financial »

Regions Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

HL

Hecla Mining

$2.59

-0.145 (-5.31%)

16:58
02/22/19
02/22
16:58
02/22/19
16:58
Syndicate
Breaking Syndicate news story on Hecla Mining »

Hecla Mining files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$50.99

0.84 (1.68%)

, CELG

Celgene

$89.15

0.54 (0.61%)

16:52
02/22/19
02/22
16:52
02/22/19
16:52
Hot Stocks
Bristol-Myers files proxy statement in connection with proposed Celgene merger »

Bristol-Myers Squibb…

BMY

Bristol-Myers

$50.99

0.84 (1.68%)

CELG

Celgene

$89.15

0.54 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 28

    Feb

  • 18

    May

  • 20

    May

  • 28

    May

TEN

Tenneco

$36.29

0.76 (2.14%)

16:48
02/22/19
02/22
16:48
02/22/19
16:48
Earnings
Tenneco sees FY19 revenue growth up 4%-5%, consensus $4.65B »

The company expects 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

TEN

Tenneco

$36.29

0.76 (2.14%)

16:46
02/22/19
02/22
16:46
02/22/19
16:46
Earnings
Tenneco reports preliminary Q4 revenue $4.3B, consensus $4.3B »

Sees FY18 EPS "near…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

XRX

Xerox

$31.50

0.16 (0.51%)

16:44
02/22/19
02/22
16:44
02/22/19
16:44
Conference/Events
Xerox management to meet with Loop Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.